Form 4 Filing - Katherine Stueland - GeneDx Holdings Corp.

On June 16, 2026, Katherine Stueland, Chief Executive Officer and Director of GeneDx Holdings Corp., engaged in several transactions involving the company's Class A Common Stock. Stueland acquired 18,750 shares through the settlement of Restricted Stock Units (RSUs) with a reported price of $0.00 per share. Concurrently, she disposed of a total of 10,499 shares. These disposals included 2,140 shares at a weighted average price of $59.7543, 5,932 shares at a weighted average price of $60.8291, and 2,429 shares at a weighted average price of $61.5035. The sales were made to cover tax withholding obligations related to the vesting of RSUs, as indicated by footnote F2, and do not represent discretionary transactions. Following these transactions, Stueland beneficially owns 104,372 shares of Class A Common Stock. She also holds RSUs convertible into up to 305,525 shares and options for up to 107,610 shares, which vest according to their terms.